Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.[1] It targets interferon a.[2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Interferon α |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C6518H10008N1724O2032S38 |
Molar mass | 146252.08 g·mol−1 |
(what is this?) (verify) |
Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.[3][4][5]